40 go as Variagenics recentres on cancer diagnostics
This article was originally published in Clinica
Executive Summary
US drugs and diagnostics developer Variagenics will reduce its R&D and administrative staff headcount by 40 in a corporate restructure that will see it focus principally on oncology molecular diagnostic programmes. The staff cuts - representing 30% of the Cambridge, Massachusetts company's posts -will help conserve cash and increase financial flexibility, says president and chief business officer Jay Mohr.